ArticleDrug design, development and therapy2025
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The tumor microenvironment (TME) has been shown to have a significant impact on lung cancer. Previously, Methods: An lung cancer mouse model was generated by subcutaneous injection of LLC cells with or without IL-10 knockdown in C57BL/6 mice or nude mice. HSF was orally administered once to the model mice daily for 15 days. Tumor growth was measured using in vivo imaging technology and vernier calipers. Hematoxylin and eosin (H&E) and Enzyme-linked immunosorbent assay (ELISA) were employed to estimate the cytotoxicity and immunological factors of the HSF treatment. Immune profiles, proliferation, apoptosis, the function of CD8 Results: HSF could inhibit tumor growth in LLC tumor model mice. Significantly, HSF reduced F4/80 Conclusion: HSF displayed antitumor immune activity by increasing the infiltration of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.